

English-Language Published, 21st Century Primary Descriptions of Phage Application to Humans

by Stephen T. Abedon, 2022

1. Weber-Dąbrowska, B, Zimecki, M, Mulczyk, M. Effective phage therapy is associated with normalization of cytokine production by blood cell cultures. *Arch Immunol Ther Exp.* 2000;48(1):31–37.
2. Weber-Dąbrowska, B, Mulczyk, M, Górski, A. Bacteriophage therapy of bacterial infections: An update of our institute's experience. *Arch Immunol Ther Exp.* 2000;48(6):547–551.
3. Weber-Dąbrowska, B, Mulczyk, M, Górski, A. Bacteriophage therapy for infections in cancer patients. *Clin Appl Immunol Rev.* 2001;1(3-4):131–134.
4. Markoishvili, K, Tsitlanadze, G, Katsarava, R, et al. A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. *Int J Dermatol.* 2002;41(7):453–458.
5. Weber-Dąbrowska, B, Zimecki, M, Mulczyk, M, et al. Effect of phage therapy on the turnover and function of peripheral neutrophils. *FEMS Immunol Med Microbiol.* 2002;34(2):135–138.
6. Weber-Dąbrowska, B, Mulczyk, M, Górski, A. Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. *Transplant Proc.* 2003;35(4):1385–1386.
7. Bruttin, A, Brüssow, H. Human volunteers receiving *Escherichia coli* phage T4 orally: a safety test of phage therapy. *Antimicrob Agents Chemother.* 2005;49(7):2874–2878.
8. Jikia, D, Chkhaidze, N, Imedashvili, E, et al. The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant *Staphylococcus aureus*-infected local radiation injuries caused by exposure to Sr⁹⁰. *Clin Exp Dermatol.* 2005;30(1):23–26.
9. Leszczyński, P, Weber-Dąbrowska, B, Kohutnicka, M, et al. Successful eradication of methicillin-resistant *Staphylococcus aureus* (MRSA) intestinal carrier status in a healthcare worker - a case report. *Folia Microbiol.* 2006;51(3):236–238.
10. Marza, JAS, Soothill, JS, Boydell, P, et al. Multiplication of therapeutically administered bacteriophages in *Pseudomonas aeruginosa* infected patients. *Burns.* 2006;32(5):644–646.
11. Weber-Dąbrowska, B, Zimecki, M, Kruzel, M, et al. Alternative therapies in antibiotic-resistant infection. *Adv Med Sci.* 2006;51:242–244.
12. Kutateladze, M, Adamia, R. Phage therapy experience at the Eliava Institute. *Med Mal Infect.* 2008;38(8):426–430.
13. Letkiewicz, S, Międzybrodzki, R, Fortuna, W, et al. Eradication of *Enterococcus faecalis* by phage therapy in chronic bacterial prostatitis—case report. *Folia Microbiol.* 2009;54(5):457–461.
14. Rhoads, DD, Wolcott, RD, Kuskowski, MA, et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. *J Wound Care.* 2009;18(6):237–244.
15. Wright, A, Hawkins, CH, Anggård, EE, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant *Pseudomonas aeruginosa*; a preliminary report of efficacy. *Clin Otolaryng.* 2009;34(4):349–357.

16. Letkiewicz, S, Międzybrodzki, R, Klak, M, et al. The perspectives of the application of phage therapy in chronic bacterial prostatitis. *FEMS Immunol Med Microbiol.* 2010;60(2):99–112.
17. Khawaldeh, A, Morales, S, Dillon, B, et al. Bacteriophage therapy for refractory *Pseudomonas aeruginosa* urinary tract infection. *J Med Microbiol.* 2011;60(11):1697–1700.
18. Kvachadze, L, Balarjishvili, N, Meskhi, T, et al. Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. *Microb Biotechnol.* 2011;4(5):643–650.
19. Międzybrodzki, R, Borysowski, J, Weber-Dąbrowska, B, et al. Clinical aspects of phage therapy. *Adv Virus Res.* 2012;83:73–121.
20. Sarker, SA, McCallin, S, Barretto, C, et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. *Virology.* 2012;434(2):222–232.
21. McCallin, S, Alam, SS, Barretto, C, et al. Safety analysis of a Russian phage cocktail: from metaGenomic analysis to oral application in healthy human subjects. *Virology.* 2013;443(2):187–196.
22. Łusiak-Szelachowska, M, Zaczek, M, Weber-Dąbrowska, B, et al. Phage neutralization by sera of patients receiving phage therapy. *Viral Immunol.* 2014;27(6):295–304.
23. Rose, T, Verbeken, G, Vos, DD, et al. Experimental phage therapy of burn wound infection: difficult first steps. *Int J Burns Trauma.* 2014;4(2):66–73.
24. Fadlallah, A, Chelala, E, Legeais, JM. Corneal infection therapy with topical bacteriophage administration. *Open Ophthalmol J.* 2015;9:167–168.
25. Kutateladze, M. Experience of the Eliava Institute in bacteriophage therapy. *Virol Sin.* 2015;30(1):80–81.
26. Fish, R, Kutter, E, Wheat, G, et al. Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. *J Wound Care.* 2016;25(Suppl 7):S27–S33.
27. Sarker, SA, Sultana, S, Reuteler, G, et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. *EBioMedicine.* 2016;4:124–137.
28. Jennes, S, Merabishvili, M, Soentjens, P, et al. Use of bacteriophages in the treatment of colistin-only-sensitive *Pseudomonas aeruginosa* septicaemia in a patient with acute kidney injury—a case report. *Crit Care.* 2017;21(1):129.
29. Łusiak-Szelachowska, M, Zaczek, M, Weber-Dąbrowska, B, et al. Antiphage activity of sera during phage therapy in relation to its outcome. *Future Microbiol.* 2017;12(2):109–117.
30. Sarker, SA, Berger, B, Deng, Y, et al. Oral application of *Escherichia coli* bacteriophage: safety tests in healthy and diarrheal children from Bangladesh. *Environ Microbiol.* 2017;19(1):237–250.
31. Schooley, RT, Biswas, B, Gill, JJ, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant *Acinetobacter baumannii* infection. *Antimicrob Agents Chemother.* 2017;61(10):e00954-17.
32. Zhvania, P, Hoyle, NS, Nadareishvili, L, et al. Phage therapy in a 16-year-old boy with Netherton syndrome. *Front Med (Lausanne).* 2017;4:94.
33. Chan, BK, Turner, PE, Kim, S, et al. Phage treatment of an aortic graft infected with *Pseudomonas aeruginosa*. *Evol Med Pub Health.* 2018;1(1):60–66.
34. Duplessis, C, Biswas, B, Hanisch, B, et al. Refractory *Pseudomonas* bacteremia in a 2-year-old sterilized by bacteriophage therapy. *J Pediatric Infect Dis Soc.* 2018;7(3):253–256.

35. Ferry, T, Leboucher, G, Fevre, C, et al. Salvage debridement, antibiotics and implant retention ("DAIR") with local injection of a selected cocktail of bacteriophages: is it an option for an elderly patient with relapsing *Staphylococcus aureus* prosthetic-joint infection? *Open Forum Infect Dis.* 2018;5(11):ofy269.
36. Ferry, T, Boucher, F, Fevre, C, et al. Innovations for the treatment of a complex bone and joint infection due to XDR *Pseudomonas aeruginosa* including local application of a selected cocktail of bacteriophages. *J Antimicrob Chemother.* 2018;73(10):2901–2903.
37. Fish, R, Kutter, E, Wheat, G, et al. Compassionate use of bacteriophage therapy for foot ulcer treatment as an effective step for moving toward clinical trials. *Meth Mol Biol.* 2018;1693:159–170.
38. Fish, R, Kutter, E, Bryan, D, et al. Resolving digital staphylococcal osteomyelitis using bacteriophage—a case report. *Antibiotics (Basel).* 2018;7(4):87.
39. Hoyle, N, Zhvaniya, P, Balarjishvili, N, et al. Phage therapy against *Achromobacter xylosoxidans* lung infection in a patient with cystic fibrosis: a case report. *Res Microbiol.* 2018;169(9):540–542.
40. LaVergne, S, Hamilton, T, Biswas, B, et al. Phage therapy for a multidrug-resistant *Acinetobacter baumannii* craniectomy site infection. *Open Forum Infect Dis.* 2018;5(4):ofy064.
41. McCallin, S, Sarker, SA, Sultana, S, et al. Metagenome analysis of Russian and Georgian Pyophage cocktails and a placebo-controlled safety trial of single phage versus phage cocktail in healthy *Staphylococcus aureus* carriers. *Environ Microbiol.* 2018;20(9):3278–3293.
42. Morozova, VV, Kozlova, YN, Ganichev, DA, et al. Bacteriophage treatment of infected diabetic foot ulcers. *Meth Mol Biol.* 2018;1693:151–158.
43. Patey, O, McCallin, S, Mazure, H, et al. Clinical indications and compassionate use of phage therapy: personal experience and literature review with a focus on osteoarticular infections. *Viruses.* 2018;11(1):18.
44. Ujmajuridze, A, Chanishvili, N, Goderdzishvili, M, et al. Adapted bacteriophages for treating urinary tract infections. *Front Microbiol.* 2018;9:1832–
45. Aslam, S, Pretorius, V, Lehman, SM, et al. Novel bacteriophage therapy for treatment of left ventricular assist device infection. *J Heart Lung Transplant.* 2019;38(4):475–476.
46. Aslam, S, Courtwright, AM, Koval, C, et al. Early clinical experience of bacteriophage therapy in three lung transplant recipients. *Am J Transplant.* 2019;19(9):2631–2639.
47. Dedrick, RM, Guerrero-Bustamante, CA, Garlena, RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant *Mycobacterium abscessus*. *Nat Med.* 2019;25(5):730–733.
48. Febvre, HP, Rao, S, Gindin, M, et al. PHAGE study: effects of supplemental bacteriophage intake on inflammation and gut microbiota in healthy adults. *Nutrients.* 2019;11(3):666.
49. Gilbey, T, Ho, J, Cooley, LA, et al. Adjunctive bacteriophage therapy for prosthetic valve endocarditis due to *Staphylococcus aureus*. *Med J Aust.* 2019;211(3):142–143.
50. Gindin, M, Febvre, HP, Rao, S, et al. Bacteriophage for gastrointestinal health (PHAGE) study: evaluating the safety and tolerability of supplemental bacteriophage consumption. *J Am Coll Nutr.* 2019;38(1):68–75.
51. Gupta, P, Singh, HS, Shukla, VK, et al. Bacteriophage therapy of chronic nonhealing wound: clinical study. *Int J Low Extrem Wounds.* 2019;18(2):171–175.
52. Jault, P, Leclerc, T, Jennes, S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by *Pseudomonas aeruginosa* (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. *Lancet Infect Dis.* 2019;19(1):35–45.

53. Kuipers, S, Ruth, MM, Mientjes, M, et al. A Dutch case report of successful treatment of chronic relapsing urinary tract infection with bacteriophages in a renal transplant patient. *Antimicrob Agents Chemother.* 2019;64(1):e01281-19–
54. Law, N, Logan, C, Yung, G, et al. Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant *Pseudomonas aeruginosa* infection in a cystic fibrosis patient. *Infection.* 2019;47(4):665–668.
55. Maddocks, S, Petrovic Fabijan, P., et al. Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by *Pseudomonas aeruginosa*. *Am J Respir Crit Care Med.* 2019;200(9):1179–1181.
56. Nir-Paz, R, Gelman, D, Khouri, A, et al. Successful treatment of antibiotic resistant poly-microbial bone infection with bacteriophages and antibiotics combination. *Clin Infect Dis.* 2019;69(11):2015–2018.
57. Onsea, J, Soentjens, P, Djebara, S, et al. Bacteriophage application for difficult-to-treat musculoskeletal infections: development of a standardized multidisciplinary treatment protocol. *Viruses.* 2019;11(10):891.
58. Ooi, ML, Drilling, AJ, Morales, S, et al. Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to *Staphylococcus aureus*. *JAMA Otolaryngol Head Neck Surg.* 2019;145(8):723–729.
59. Rogóz, P, Amanatullah, DF, Międzybrodzki, R, et al. Phage therapy in orthopaedic implant-associated infections. In: *Phage Therapy: A Practical Approach.* (Górski, A, Międzybrodzki, R, Borysowski, J. eds.) Springer Nature Switzerland AG: 2019;189–211.
60. Tkhalishvili, T, Winkler, T, Muller, M, et al. Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2019;64(1):e00924-19.
61. Aslam, S, Lampley, E, Wooten, D, et al. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. *Open Forum Infect Dis.* 2020;7(9):ofaa389.
62. Bao, J, Wu, N, Zeng, Y, et al. Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant *Klebsiella pneumoniae*. *Emerg Microbes Infect.* 2020;9(1):771–774.
63. Corbellino, M, Kieffer, N, Kutateladze, M, et al. Eradication of a multidrug-resistant, carbapenemase-producing *Klebsiella pneumoniae* isolate following oral and intra-rectal therapy with a custom made, lytic bacteriophage preparation. *Clin Infect Dis.* 2020;70(9):1998–2001.
64. Doub, JB, Ng, VY, Johnson, AJ, et al. Salvage bacteriophage therapy for a chronic MRSA prosthetic joint infection. *Antibiotics (Basel).* 2020;9(5):241.
65. Ferry, T, Kolenda, C, Batailler, C, et al. Phage therapy as adjuvant to conservative surgery and antibiotics to salvage patients with relapsing *S. aureus* prosthetic knee infection. *Front Med (Lausanne).* 2020;7:570572.
66. Ferry, T, Batailler, C, Petitjean, C, et al. The potential innovative use of bacteriophages within the DAC® hydrogel to treat patients with knee megaprosthesis infection requiring "Debridement antibiotics and implant retention" and soft tissue coverage as salvage therapy. *Front Med (Lausanne).* 2020;7:342.
67. Gainey, AB, Burch, AK, Brownstein, MJ, et al. Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant *Achromobacter* species infection in a pediatric cystic fibrosis patient. *Pediatr Pulmonol.* 2020;55(11):2990– 2994.
68. Grubb, DS, Wrigley, SD, Freedman, KE, et al. PHAGE-2 study: supplemental bacteriophages extend *Bifidobacterium animalis* subsp. *lactis* BL04 benefits on gut health and microbiota in healthy adults. *Nutrients.* 2020;12(8):2474.

69. Petrovic Fabijan, P, Lin, RCY, et al. Safety of bacteriophage therapy in severe *Staphylococcus aureus* infection. *Nat Microbiol.* 2020;5(3):465–472.
70. Qin, J, Wu, N, Bao, J, et al. Heterogeneous *Klebsiella pneumoniae* co-infections complicate personalized bacteriophage therapy. *Front Cell Infect Microbiol.* 2020;10:608402.
71. Rubalskii, E, Ruemke, S, Salmoukas, C, et al. Bacteriophage therapy for critical infections related to cardiothoracic surgery. *Antibiotics (Basel).* 2020;9(5):232.
72. Cano, EJ, Caflich, KM, Bollyky, PL, et al. Phage therapy for limb-threatening prosthetic knee *Klebsiella pneumoniae* infection: case report and *in vitro* characterization of anti-biofilm activity. *Clin Infect Dis.* 2021;73(1):e144–e151.
73. Dedrick, RM, Freeman, KG, Nguyen, JA, et al. Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary *Mycobacterium abscessus* infection. *Nat Med.* 2021;27(8):1357–1361.
74. Doub, JB, Ng, VY, Wilson, E, et al. Successful treatment of a recalcitrant *Staphylococcus epidermidis* prosthetic knee infection with intraoperative bacteriophage therapy. *Pharmaceuticals.* 2021;14(3):231.
75. Ferry, T, Kolenda, C, Batailler, C, et al. Case report: Arthroscopic "Debridement Antibiotics and Implant Retention" with local injection of personalized phage therapy to salvage a relapsing *Pseudomonas aeruginosa* prosthetic knee infection. *Front Med (Lausanne).* 2021;8:569159.
76. Jernigan, DA, Hart, MC, Dodd, KK, et al. Induced native phage therapy for the treatment of Lyme disease and relapsing fever: a retrospective review of first 14 months in one clinic. *Cureus.* 2021;13(11):e20014.
77. Johri, AV, Johri, P, Hoyle, N, et al. Case report: Chronic bacterial prostatitis treated with phage therapy after multiple failed antibiotic treatments. *Front Pharmacol.* 2021;12:692614.
78. Khatami, A, Lin, RCY, Petrovic-Fabijan, A, et al. Bacterial lysis, autophagy and innate immune responses during adjunctive phage therapy in a child. *EMBO Mol Med.* 2021;13(9):e13936.
79. Lebeaux, D, Merabishvili, M, Caudron, E, et al. A case of phage therapy against pandrug-resistant *Achromobacter xylosoxidans* in a 12-year-old lung-transplanted cystic fibrosis patient. *Viruses.* 2021;13(1):60.
80. Leitner, L, Ujmajuridze, A, Chanishvili, N, et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. *Lancet Infect Dis.* 2021;21(3):427–436.
81. Łusiak-Szelachowska, M, Międzybrodzki, R, Fortuna, W, et al. Anti-phage serum antibody responses and the outcome of phage therapy. *Folia Microbiol.* 2021;66(1):127–131.
82. Neuts, AS, Berkhout, HJ, Hartog, A, et al. Bacteriophage therapy cures a recurrent phenom: phage therapy infected total hip arthroplasty? A case report. *Acta Orthop.* 2021;92(6):678–680.
83. Patel, DR, Bhartiya, SK, Kumar, R, et al. Use of customized bacteriophages in the treatment of chronic nonhealing wounds: a prospective study. *Int J Low Extrem Wounds.* 2021;20(1):37–46.
84. Paul, K, Merabishvili, M, Hazan, R, et al. Bacteriophage rescue therapy of a vancomycin-resistant *Enterococcus faecium* infection in a one-year-old child following a third liver transplantation. *Viruses.* 2021;13(9):1785.
85. Ramirez-Sanchez, C, Gonzales, F, Buckley, M, et al. Successful treatment of *Staphylococcus aureus* prosthetic joint infection with bacteriophage therapy. *Viruses.* 2021;13(6):1182.
86. Rostkowska, OM, Międzybrodzki, R, Miszewska-Szyszkowska, D, et al. Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient. The use of phage therapy. *Transpl Infect Dis.* 2021;23(1):e13391.

87. Tan, X, Chen, H, Zhang, M, et al. Clinical experience of personalized phage therapy against carbapenem-resistant *Acinetobacter baumannii* lung infection in a patient with chronic obstructive pulmonary disease. *Front Cell Infect Microbiol.* 2021;11:631585.
88. Terwilliger, A, Clark, J, Karris, M, et al. Phage therapy related microbial succession associated with successful clinical outcome for a recurrent urinary tract infection. *Viruses.* 2021;13(10):2049.
89. Tkhilaishvili, T, Merabishvili, M, Pirnay, JP, et al. Successful case of adjunctive intravenous bacteriophage therapy to treat left ventricular assist device infection. *J Infect.* 2021;83(3):e1–e3.
90. Van, NB, Galant, C, Brichard, B, et al. A case of in situ phage therapy against *Staphylococcus aureus* in a bone allograft polymicrobial biofilm infection: outcomes and phage-antibiotic interactions. *Viruses.* 2021;13(10):1898.
91. Wu, N, Dai, J, Guo, M, et al. Pre-optimized phage therapy on secondary *Acinetobacter baumannii* infection in four critical COVID-19 patients. *Emerg Microbes Infect.* 2021;10(1):612–618.
92. Zaldastanishvili, E, Leshkasheli, L, Dadiani, M, et al. Phage therapy experience at the Eliava Phage Therapy Center: three cases of bacterial persistence. *Viruses.* 2021;13(10):1901.
93. Bhartiya, SK, Prasad, R, Sharma, S, et al. Biological therapy on infected traumatic wounds: a case-control study. *Int J Low Extrem Wounds.* 2022; <https://doi.org/10.1177/15347346211072779>.
94. Chen, P, Liu, Z, Tan, X, et al. Bacteriophage therapy for empyema caused by carbapenem-resistant *Pseudomonas aeruginosa*. *Biosci Trends.* 2022;16(2):158–162.
95. Doub, JB, Wilson, E. Observed transaminitis with a unique bacteriophage therapy protocol to treat recalcitrant staphylococcal biofilm infections. *Infection.* 2022;50(1):281–283.
96. Ferry, T, Kolenda, C, Briot, T, et al. Implementation of a complex bone and joint infection phage therapy centre in France: lessons to be learned after 4 years' experience. *Clin Microbiol Infect.* 2022;28(1):145–146.
97. Little, JS, Dedrick, RM, Freeman, KG, et al. Bacteriophage treatment of disseminated cutaneous *Mycobacterium chelonae* infection. *Nat Commun.* 2022;13(1):2313.
98. Rao, S, Betancourt-Garcia, M, Kare-Opaneye, YO, et al. Critically ill patient with multidrug-resistant *Acinetobacter baumannii* respiratory infection successfully treated with intravenous and nebulized bacteriophage therapy. *Antimicrob Agents Chemother.* 2022;66(1):e0082421.
99. Rodriguez, JM, Woodworth, BA, Horne, B, et al. Case Report: successful use of phage therapy in refractory MRSA chronic rhinosinusitis. *Int J Infect Dis.* 2022;121:14–16.
100. Simner, PJ, Cherian, J, Suh, GA, et al. Combination of phage therapy and cefiderocol to successfully treat *Pseudomonas aeruginosa* cranial osteomyelitis. *JAC Antimicrob Resist.* 2022;4(3):dlac046.
101. Schoeffel, J, Wang, EW, Gill, D, et al. Successful use of salvage bacteriophage therapy for a recalcitrant MRSA knee and hip prosthetic joint infection. *Pharmaceuticals.* 2022;15(2):177.
102. Tkhilaishvili, T, Potapov, E, Starck, C, et al. Bacteriophage therapy as a treatment option for complex cardiovascular implant infection: the German Heart Center Berlin experience. *J Heart Lung Transplant.* 2022;41(5):551–555.